Key Highlights
- ZEVASKYN generated USD 13.49 million of revenue; the market had expected USD 14.82 million.
- A USD 0.08 loss per share compared with an expected loss of USD 0.17.
- Treatments reached 15 since launch, six of them in the quarter.
- Abeona bought ABO-801 from Ellodi Pharmaceuticals; closing is listed as November 9.
Abeona Therapeutics (NASDAQ:ABEO) ended the third quarter of 2026 with USD 13.49 million in Revenue and a loss of USD 0.08 per share. The market had expected revenue of USD 14.82 million and a loss of USD 0.17 per share. ZEVASKYN, the source of the revenue, is a gene therapy that is autologous and cell-based, aimed at wounds suffered by adults and children affected by recessive dystrophic epidermolysis bullosa.
Management put ZEVASKYN net revenue at USD 13.5 million, an 18% increase on the prior quarter. The figures were released as the company announced its purchase of APT-1011, now called ABO-801, from Ellodi Pharmaceuticals. The filing lists November 9, 2026 as the closing date.
From Patient Count to Revenue Line
ZEVASKYN reached six patients in the quarter, lifting the cumulative count since launch to 15. Of the six treatments, five yielded recognized revenue. Management said the sixth was left out because the batch involved failed the pan-CK identity assay specification.
CHOP and UTMB, both activated qualified treatment centers, each treated a first patient during the quarter. Four treatment centers now have experience with ZEVASKYN. According to the filing, no center is obliged to use it, and Abeona holds no contractual right to be paid before final quality inspection is complete and control transfers.
Expense Lines, Interest and a Non-Cash Warrant Gain
The USD 5.7 million cost of sales is largely the cost of selling ZEVASKYN commercially, along with royalties payable to Stanford, the licensor. R&D outlays came to USD 3.7 million, versus USD 4.2 million the previous year. SG&A costs were USD 17.1 million, versus USD 19.3 million.
Abeona earned USD 2.3 million in interest, against USD 1.7 million, and paid USD 0.6 million, against USD 0.9 million. Remeasuring the warrant liabilities at Fair Value produced a non-cash gain of USD 6.5 million, where the earlier period had a gain of USD 2.8 million. The filing credits a lower share price during the quarter and the shrinking time left on the warrants.
A Second Asset and a 12-Month Funding Window
Abeona judges its existing Capital adequate to pay for operations and capital spending for a minimum of 12 months after the date the financial statements were issued. In development, the company has ABO-701, an engineered T-cell therapy that targets PSMA in solid tumors. Commercial Supply of ZEVASKYN comes from its Cleveland, Ohio plant, which manufactures cell and gene therapies.
Management described the ABO-801 purchase as a way to extend the company's reach past ZEVASKYN. It called ZEVASKYN the base of the Business and the most pressing operational focus.






Please wait processing your request...